The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2

References

• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. doi:10.1056/NEJMoa2001017.
   PubMed Web of Science ®Google Scholar
• Coronaviridae Study Group of the International Committee on Taxonomy of V. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–44. doi:10.1038/s41564-020-0695-z.
   PubMed Web of Science ®Google Scholar
• WHO. WHO director-general’s opening remarks at the media briefing on COVID-19-11 March 2020. 2020; [accessed 2020 March 11]. https://webarchiveorg/web/20200311212521/https://wwwwhoint/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
   Google Scholar
• Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–69. doi:10.1001/jama.2020.1585.
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, Bucci E, Piacentini M, Ippolito G, Melino G, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27:1451–54. doi:10.1038/s41418-020-0530-3.
   PubMed Web of Science ®Google Scholar
• Ulrich H, Pillat MM. CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Rep. 2020. doi:10.1007/s12015-020-09976-7.
   Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–92 e6. doi:10.1016/j.cell.2020.02.058.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(4):894–904.e9. doi:10.1016/j.cell.2020.03.045. Epub 2020 Apr 9.
   Google Scholar
• Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30:343–55. doi:10.1038/s41422-020-0305-x.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80 e8. doi:10.1016/j.cell.2020.02.052.
   PubMed Web of Science ®Google Scholar
• Bello M, Martinez-Munoz A, Balbuena-Rebolledo I. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA. J Mol Model. 2020;26:340. doi:10.1007/s00894-020-04600-4.
   PubMed Web of Science ®Google Scholar
• Chen YW, Yiu CB, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 2020;9:129. doi:10.12688/f1000research.22457.2.
   PubMedGoogle Scholar
• Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16:69.
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
   PubMedGoogle Scholar
• Rosendahl Huber S, van Beek J, de Jonge J, Luytjes W, van Baarle D. T cell responses to viral infections - opportunities for Peptide vaccination. Front Immunol. 2014;5:171. doi:10.3389/fimmu.2014.00171.
   PubMed Web of Science ®Google Scholar
• Murphy K, Weaver C. Janeway’s immunobiology. Garland Sci. 2016. ISBN: 978-3-662-56003-7.
   Google Scholar
• Zajac A, Harrington L. Immune response to viruses: cell-mediated immunity. In: Encyclopedia of virology. Ed Elsevier Ltd; 2008. doi:10.1016/B978-012374410-4.00799-8. Corpus Corpus ID: 81055973.
   Google Scholar
• Cecere TE, Todd SM, Leroith T. Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? Viruses. 2012;4:833–46. doi:10.3390/v4050833.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517. doi:10.1146/annurev.immunol.021908.132710.
   PubMed Web of Science ®Google Scholar
• Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D. Broad and strong memory CD4 (+) and CD8 (+) T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients. bioRxiv. 2020;21(11):1336–1345. doi:10.1038/s41590-020-0782-6. Epub 2020 Sep 4.
   Google Scholar
• Zhang S, Zhang H, Zhao J. The role of CD4 T cell help for CD8 CTL activation. Biochem Biophys Res Commun. 2009;384:405–08. doi:10.1016/j.bbrc.2009.04.134.
   PubMed Web of Science ®Google Scholar
• Gupta S, Su H, Narsai T, Agrawal S. SARS-CoV-2-associated T-cell responses in the presence of humoral immunodeficiency. Int Arch Allergy Immunol. 2021;182:195–209. doi:10.1159/000514193.
   PubMed Web of Science ®Google Scholar
• Maloir Q, Ghysen K, Louis R, Guiot J. Acute respiratory distress revealing antisynthetase syndrome. Rev Med Liege. 2018;73:370–75.
   PubMedGoogle Scholar
• Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, Gale MJ, Baric RS, Enjuanes L, Gallagher T, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111:4970–75. doi:10.1073/pnas.1323279111.
   PubMed Web of Science ®Google Scholar
• Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, Subbarao K. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010;84(3):1289–301. doi:10.1128/JVI.01281-09.
   PubMed Web of Science ®Google Scholar
• Li CK-F, Wu H, Yan H, Ma S, Wang L, Zhang M, Tang X, Temperton NJ, Weiss RA, Brenchley JM, et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008;181:5490–500. doi:10.4049/jimmunol.181.8.5490.
   PubMed Web of Science ®Google Scholar
• Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020. doi:10.1016/j.jmii.2020.03.005.
   Google Scholar
• Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–34. doi:10.1016/S0140-6736(20)30628-0.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020:102537. doi:10.1016/j.autrev.2020.102537.
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, Kronbichler A, Shin JI. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11:316–29. doi:10.7150/thno.49713.
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020. doi:10.1001/jama.2020.4783.
   PubMed Web of Science ®Google Scholar
• Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, Lang C, Xiao Q, Xiao K, Yi Z, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020 Feb 10:20021832.
   Google Scholar
• Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–73. doi:10.1038/s41586-020-2012-7.
   PubMed Web of Science ®Google Scholar
• Ng O-W, Chia A, Tan AT, Jadi RS, Leong HN, Bertoletti A, Tan Y-J. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016;34:2008–14. doi:10.1016/j.vaccine.2016.02.063.
   PubMed Web of Science ®Google Scholar
• Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5:917–27. doi:10.1038/nri1732.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020. doi:10.1016/S2213-2600(20)30076-X.
   Web of Science ®Google Scholar
• Wang K, Chen W, Zhou Y-S, Lian J-Q, Zhang Z, Du P, Gong L, Zhang Y, Cui HY, Geng JJ, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020 Dec 4;5(1):283. doi:10.1038/s41392-020-00426-x.
   Google Scholar
• Shin HS, Kim Y, Kim G, Lee JY, Jeong I, Joh JS, Kim H, Chang E, Sim SY, Park J-S, et al. Immune responses to middle east respiratory syndrome coronavirus during the acute and convalescent phases of human infection. Clin Infect Dis. 2019;68:984–92. doi:10.1093/cid/ciy595.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, Agnihothram S, Baric R, David C, Perlman S, et al. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity. 2016;44:1379–91. doi:10.1016/j.immuni.2016.05.006.
   PubMed Web of Science ®Google Scholar
• Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L, Hoffmann M, Pöhlmann S, et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell. 2020;181(5):1004–15 e15. doi:10.1016/j.cell.2020.04.031.
   PubMed Web of Science ®Google Scholar
• Cromer D, Juno JA, Khoury D, Reynaldi A, Wheatley AK, Kent SJ, Davenport MP. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021. doi:10.1038/s41577-021-00550-x.
   PubMed Web of Science ®Google Scholar
• Haveri A, Smura T, Kuivanen S, Österlund P, Hepojoki J, Ikonen N, Pitkäpaasi M, Blomqvist S, Rönkkö E, Kantele A, et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020;25(11):2000266. doi:10.2807/1560-7917.ES.2020.25.11.2000266.
   PubMedGoogle Scholar
• Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, Wang -Y-Y, Xiao G-F, Yan B, Shi Z-L, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386–89. doi:10.1080/22221751.2020.1729071.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhou B, Li M, Liang X, Wang H, Yang G, Wang H, Le X. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis. 2004;189(7):1158–63. doi:10.1086/380397.
   PubMed Web of Science ®Google Scholar
• Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, Lv Q, Liu J, Yu P, Xu Y, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. 2020 Mar 13:990226. doi:10.1101/2020.03.13.990226.
   Google Scholar
• Casadevall A. Pirofski L-a. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130:1545–48.
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Nat Acad Sci. 2020Apr 28;117(17):9490–9496.
   Web of Science ®Google Scholar
• Wang S-F, Tseng S-P, Yen C-H, Yang J-Y, Tsao C-H, Shen C-W, Chen K-H, Liu F-T, Liu W-T, Chen YMA, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451(2):208–14. doi:10.1016/j.bbrc.2014.07.090.
   PubMed Web of Science ®Google Scholar
• Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38:10–18. doi:10.12932/AP-200220-0773.
   PubMed Web of Science ®Google Scholar
• Hartley GE, Edwards ESJ, Aui PM, Varese N, Stojanovic S, McMahon J, Peleg AY, Boo I, Drummer HE, Hogarth PM, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol. 2020;5(54):eabf8891. doi:10.1126/sciimmunol.abf8891.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. doi:10.1126/science.abf4063.
   PubMed Web of Science ®Google Scholar
• Sosa-Hernández VA, Torres-Ruíz J, Cervantes-Díaz R, Romero-Ramírez S, Páez-Franco JC, Meza-Sánchez DE, Juárez-Vega G, Pérez-Fragoso A, Ortiz-Navarrete V, Ponce-de-León A, et al. B cell subsets as severity-associated signatures in COVID-19 patients. Front Immunol. 2020:11. doi:10.3389/fimmu.2020.611004.
   PubMedGoogle Scholar
• Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, Alanio C, Kuri-Cervantes L, Pampena MB, D’Andrea K, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369:eabc8511.
   PubMed Web of Science ®Google Scholar
• Oliviero B, Varchetta S, Mele D, Mantovani S, Cerino A, Perotti CG, Ludovisi S, Mondelli MU. Expansion of atypical memory B cells is a prominent feature of COVID-19. Cell Mol Immunol. 2020;17:1101–03. doi:10.1038/s41423-020-00542-2.
   PubMed Web of Science ®Google Scholar
• Mubarak A, Alturaiki W, Hemida MG. Middle east respiratory syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J Immunol Res. 2019;2019:6491738. doi:10.1155/2019/6491738.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. doi:10.1016/S0140-6736(20)30211-7.
   PubMed Web of Science ®Google Scholar
• Snijder EJ, van der Meer Y, Zevenhoven-Dobbe J, Onderwater JJ, van der Meulen J, Koerten HK, Mommaas AM. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J Virol. 2006;80(12):5927–40. doi:10.1128/JVI.02501-05.
   PubMed Web of Science ®Google Scholar
• Niemeyer D, Zillinger T, Muth D, Zielecki F, Horvath G, Suliman T, Barchet W, Weber F, Drosten C, Muller MA, et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol. 2013;87(22):12489–95. doi:10.1128/JVI.01845-13.
   PubMed Web of Science ®Google Scholar
• Menachery VD, Schafer A, Burnum-Johnson KE, Mitchell HD, Eisfeld AJ, Walters KB, Nicora CD, Purvine SO, Casey CP, Monroe ME, et al. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc Natl Acad Sci U S A. 2018;115(5):E1012–E21. doi:10.1073/pnas.1706928115.
   PubMed Web of Science ®Google Scholar
• Canton J, Fehr AR, Fernandez-Delgado R, Gutierrez-Alvarez FJ, Sanchez-Aparicio MT, Garcia-Sastre A, Perlman S, Enjuanes L, Sola I. MERS-CoV 4b protein interferes with the NF-kappaB-dependent innate immune response during infection. PLoS Pathog. 2018;14:e1006838. doi:10.1371/journal.ppat.1006838.
   PubMed Web of Science ®Google Scholar
• Yang JR, Deng DT, Wu N, Yang B, Li HJ, Pan XB. Persistent viral RNA positivity during recovery period of a patient with SARS-CoV-2 infection. J Med Virol. 2020. doi:10.1002/jmv.25940.
   Web of Science ®Google Scholar
• Thoms M, Buschauer R, Ameismeier M, Koepke L, Denk T, Hirschenberger M, Kratzat H, Hayn M, Mackens-Kiani T, Cheng J, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science. 2020;369:1249–55. doi:10.1126/science.abc8665.
   PubMed Web of Science ®Google Scholar
• Xia H, Cao Z, Xie X, Zhang X, Chen JY, Wang H, Menachery VD, Rajsbaum R, Shi P-Y. Evasion of type i interferon by SARS-CoV-2. Cell Rep. 2020;33(1):108234. doi:10.1016/j.celrep.2020.108234.
   PubMed Web of Science ®Google Scholar
• Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, Schulz L, Widera M, Mehdipour AR, Tascher G, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587(7835):657–62. doi:10.1038/s41586-020-2601-5.
   PubMed Web of Science ®Google Scholar
• Vithani N, Ward MD, Zimmerman MI, Novak B, Borowsky JH, Singh S, Bowman GR. SARS-CoV-2 Nsp16 activation mechanism and a cryptic pocket with pan-coronavirus antiviral potential. Biophys J. 2021. doi:10.1016/j.bpj.2021.03.024.
   PubMed Web of Science ®Google Scholar
• Majumdar P, Niyogi S. ORF3a mutation associated with higher mortality rate in SARS-CoV-2 infection. Epidemiol Infect. 2020;148:e262. doi:10.1017/S0950268820002599.
   PubMed Web of Science ®Google Scholar
• Zinzula L. Lost in deletion: the enigmatic ORF8 protein of SARS-CoV-2. Biochem Biophys Res Commun. 2021;538:116–24. doi:10.1016/j.bbrc.2020.10.045.
   PubMed Web of Science ®Google Scholar
• Ramirez Hernandez E, Hernandez-Zimbron LF, Martinez Zuniga N, Leal-Garcia JJ, Ignacio Hernandez V, Ucharima-Corona LE, Pérez Campos E, Zenteno E. The role of the SARS-CoV-2 S-protein glycosylation in the Interaction of SARS-CoV-2/ACE2 and immunological responses. Viral Immunol. 2021;34:165–73. doi:10.1089/vim.2020.0174.
   PubMed Web of Science ®Google Scholar
• Thomas S. The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter SemiSWEET. Pathog Immun. 2020;5:342–63. doi:10.20411/pai.v5i1.377.
   PubMedGoogle Scholar
• Zhou T, Tsybovsky Y, Gorman J, Rapp M, Cerutti G, Chuang G-Y, Katsamba PS, Sampson JM, Schön A, Bimela J, et al. Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains. Cell Host Microbe. 2020;28(6):867–79 e5. doi:10.1016/j.chom.2020.11.004.
   PubMed Web of Science ®Google Scholar
• Lu F. SARS-CoV-2 ORF9c: a mysterious membrane-anchored protein that regulates immune evasion? Nat Rev Immunol. 2020;20:648. doi:10.1038/s41577-020-00449-z.
   PubMedGoogle Scholar
• Khan RJ, Jha RK, Singh E, Jain M, Amera GM, Singh RP, Muthukumaran J, Singh AK. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an in silico assisted drug-repurposing study. J Biomol Struct Dyn. 2020:1–11. doi:10.1080/07391102.2020.1814870.
   Web of Science ®Google Scholar
• DrugBank. ChAdOx1 nCoV-19; 2020.
   Google Scholar
• Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, Mair C, Makinson R, Sheridan J, Rohde C, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020;20(7):816–26. doi:10.1016/S1473-3099(20)30160-2.
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38:1–9. doi:10.12932/AP-200220-0772.
   PubMed Web of Science ®Google Scholar
• Lu S. Timely development of vaccines against SARS-CoV-2. Emerg Microbes Infect. 2020;9:542–44. doi:10.1080/22221751.2020.1737580.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021;50(2):279–83. doi:10.1093/ageing/afaa274.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81. doi:10.1016/S0140-6736(21)00234-8.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021. doi:10.1056/NEJMoa2034201.
   Web of Science ®Google Scholar
• Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397(10275):642–43. doi:10.1016/S0140-6736(21)00191-4.
   PubMed Web of Science ®Google Scholar
• Palacios R, Patino EG, de Oliveira Piorelli R, Conde M, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) vaccine manufactured by Sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):853. doi:10.1186/s13063-020-04775-4.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–60. doi:10.1001/jama.2020.15543.
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021;372:n296. doi:10.1136/bmj.n296.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W, Wu X, Yan Y, Zhao W, Wu J, et al. COVID-19: coronavirus vaccine development updates. Front Immunol. 2020;11:602256. doi:10.3389/fimmu.2020.602256.
   PubMed Web of Science ®Google Scholar
• Garg H, Mehmetoglu-Gurbuz T, Joshi A. Recent advances in zika virus vaccines. Viruses. 2018:10. doi:10.3390/v10110631.
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J, Avanzato VA, Bushmaker T, Flaxman A, Ulaszewska M, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020 Oct;586(7830):578–582. doi:10.1038/s41586-020-2608-y. Epub 2020 Jul 30.
   Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Meyer M, Wang Y, Edwards D, Smith GR, Rubenstein AB, Ramanathan P, Mire CE, Pietzsch C, Chen X, Ge Y, et al. mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge. bioRxiv. 2021. doi:10.1101/2021.01.25.428136.
   Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–91.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–93. doi:10.1016/S0140-6736(20)32466-1.
   PubMed Web of Science ®Google Scholar
• Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020:12. doi:10.3390/v12030254.
   PubMed Web of Science ®Google Scholar
• Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020Jun 2;16(6):1232–1238. doi:10.1080/21645515.2020.1735227. Epub 2020 Mar 18.
   Web of Science ®Google Scholar
• Shieber J. Codagenix raises $20 million for a new flu vaccine and other therapies. Tech Crunch; [ accessed 2020 Feb 28]. https://techcrunchcom/2020/01/13/codagenix-raises-20-million-for-a-new-flu-vaccine-and-other-therapies/. Return to ref 23 in article 2020.
   Google Scholar
• Plotkin S. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47:401–09. doi:10.1086/589862.
   PubMed Web of Science ®Google Scholar
• Qiang GLB, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, et al. Rapid development of an inactivated vaccine for SARS-CoV-2. Science. 2020 Jul 3;369(6499):77–81. doi:10.1126/science.abc1932. Epub 2020 May 6.
   Google Scholar
• Zverev VV, Katlinskii AV, Kostinov MP, Zhirova SN, Erofeeva MK, Stukova MA, Korovkin SA, Mel’nikov SI, Semchenko AV, Mironov AN, et al. Comparative clinical trial of vaccines against avian influenza. Zh Mikrobiol Epidemiol Immunobiol. 2007;(3):10–6.
   Google Scholar
• Yang ZN, Zhao YY, Li L, Gao HD, Cai Q, Sun XX, Zhang FS, Su JF, Zhang YN, Shu X, et al. Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use. Zhonghua Liu Xing Bing Xue Za Zhi. 2021;42:1–6. doi:10.3760/cma.j.cn112338-20210325-00249.
   PubMedGoogle Scholar
• Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–92. doi:10.1016/S1473-3099(20)30843-4.
   PubMed Web of Science ®Google Scholar
• Hemida MG, Ba Abduallah MM. The SARS-CoV-2 outbreak from a one health perspective. One Health. 2020:100127. doi:10.1016/j.onehlt.2020.100127.
   PubMed Web of Science ®Google Scholar
• Zhu X, Liu Q, Du L, Lu L, Jiang S. Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis. 2013:S142–S8. doi:10.3978/j.2072-1439.2013.06.06.
   PubMed Web of Science ®Google Scholar
• Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI, Gutierrez RA, Gwee SXW, Chua PEY, Yang Q, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. J Clin Med. 2020:9. doi:10.3390/jcm9030623.
   PubMed Web of Science ®Google Scholar
• Biopharmaceuticals C. Clover initiates development of recombinant subunit-trimer vaccine for Wuhan coronavirus (2019-nCoV). 2020:2020. AP news Press release,01/28/2020, avaliable at https://apnews.com/press-release/pr-businesswire/fe24e251ddb843a9b091561a06f8eead
   Google Scholar
• Zhang Y, Zhao W, Mao Y, Chen Y, Wang S, Zhong Y, Su T, Gong M, Du D, Lu X, et al. Site-specific N-glycosylation characterization of recombinant SARS-CoV-2 spike proteins. Mol Cell Proteomics. 2021;20:100058. doi:10.1074/mcp.RA120.002295.
   PubMed Web of Science ®Google Scholar
• McKee A, MacLeod M, Kappler J, Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol. 2010;8:37. doi:10.1186/1741-7007-8-37.
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol. 2005;175:633–39. doi:10.4049/jimmunol.175.2.633.
   PubMed Web of Science ®Google Scholar
• Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis. 2011;53:296–302. doi:10.1093/cid/cir334.
   PubMed Web of Science ®Google Scholar
• Yuan M, Huang D, Lee CD, Wu NC, Jackson AM, Zhu X, Liu H, Peng L, van Gils MJ, Sanders RW, et al. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. bioRxiv. 2021 May 20;eabh1139. doi:10.1126/science.abh1139.
   Google Scholar
• Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184(9):2348–2361.e6. doi:10.1016/j.cell.2021.02.037.
   PubMed Web of Science ®Google Scholar
• Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Ellebedy A, et al. Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv. 2020Nov 8;2020.11.06.372037. doi:10.1101/2020.11.06.372037.
   Google Scholar
• Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann -H-H, Michailidis E, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020:9. doi:10.7554/eLife.61312.
   Web of Science ®Google Scholar
• Hemida MG. The next-generation coronavirus diagnostic techniques with particular emphasis on the SARS-CoV-2. J Med Virol. 2021. doi:10.1002/jmv.26926.
   Web of Science ®Google Scholar
• Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, Bennett H, Boyoglu-Barnum S, Shi W, Graham BS, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021 Jan 25;2021.01.25.427948. doi:10.1101/2021.01.25.427948.
   Google Scholar
• Felgenhauer U, Schoen A, Gad HH, Hartmann R, Schaubmar AR, Failing K, Drosten C, Weber F. Inhibition of SARS-CoV-2 by type I and type III interferons. J Biol Chem. 2020;295:13958–64. doi:10.1074/jbc.AC120.013788.
   PubMed Web of Science ®Google Scholar
• Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020;136:2080–89. doi:10.1182/blood.2020008248.
   PubMed Web of Science ®Google Scholar
• Volpatti LR, Wallace RP, Cao S, Raczy MM, Wang R, Gray LT, Alpar AT, Briquez PS, Mitrousis N, Marchell TM, et al. Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity. bioRxiv. 2021. doi:10.1101/2021.04.08.438884.
   PubMedGoogle Scholar
• Li S, Jiang L, Li X, Lin F, Wang Y, Li B, Jiang T, An W, Liu S, Liu H, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020Jun 18;5(12):e138070. doi:10.1172/jci.insight.138070.
   Web of Science ®Google Scholar
• Shirato K, Kizaki T. SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages. Heliyon. 2021;7:e06187. doi:10.1016/j.heliyon.2021.e06187.
   PubMed Web of Science ®Google Scholar
• Root-Bernstein R. Innate receptor activation patterns involving TLR and NLR synergisms in COVID-19, ALI/ARDS and sepsis cytokine storms: a review and model making novel predictions and therapeutic suggestions. Int J Mol Sci. 2021:22. doi:10.3390/ijms22042108.
   PubMed Web of Science ®Google Scholar
• Zuin M, Rigatelli G, Zuliani G, Roncon L. Fatigue as long-term consequence of ARDS in COVID-19 patients. Anaesth Crit Care Pain Med. 2021;40:100787. doi:10.1016/j.accpm.2020.10.016.
   PubMed Web of Science ®Google Scholar